The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Published: 27 June 2022

  • Views:

    Views Icon 7148

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Taking the recent ACC heart failure guideline updates as its core theme, this symposium, part of Heart Failure Online 2022, provides a succinct overview of the changes with one of the guideline’s primary authors.

 

The faculty then consider how guidelines have evolved to accommodate the growing number of foundational treatments for heart failure and how we are moving towards personalised care. We also take a look at HFpEF, and assess how our treatment options have changed and what else can be expected for this population.

This symposium has been supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

Upon participation in this programme physicians should be able to:

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

More from this programme

Part 1

The ACC Heart Failure Guidelines 2022: What Did We Learn?

1 session
The ACC Heart Failure Guidelines 2022: What Did We Learn? Watch now

Part 2

The Future of Guidelines: Towards Personalised Care?

1 session
The Future of Guidelines: Towards Personalised Care? Watch now

Part 3

HFpEF: The Final Chapter in the Heart Failure Story?

1 session
HFpEF: The Final Chapter in the Heart Failure Story? Watch now

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile